Emphysema Clinical Trials 2024

Emphysema Clinical Trials 2024

Emphysema research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in emphysema clinical trials today.

Trials for COPD Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to emphysema

What are the top hospitals conducting emphysema research?

When it comes to cutting-edge clinical trials in the realm of emphysema, several hospitals across the United States are leading the charge. In Charleston, South carolina, the Medical University of South Carolina is at the forefront with three ongoing emphysema trials and a total of ten completed studies dedicated to this debilitating condition. The hospital's involvement in emphysema research dates back to 2007 when they recorded their first-ever trial on this disease. Another notable institution making significant strides is Boston's Beth Israel Deaconess Medical Center. With three active emphysema trials and seven previously conducted ones, their commitment to finding innovative solutions began in 2006.

The University of Alabama at Birmingham has also emerged as a key player in exploring potential treatments for emphysema. Currently undertaking two active trials and having completed eleven previous ones since initiating their first trial in 2007, this esteemed university continues to contribute significantly to our understanding of this respiratory disorder. Meanwhile, Denver's National Jewish Medical and Research Center has been conducting groundbreaking research on emphysema since recording its inaugural trial back in 2003. With two ongoing trials and four completed studies under its belt, this center remains dedicated to improving outcomes for patients with this chronic lung condition.

Last but not least among these trailblazers is Columbia University based in New york City—the epicenter of medical advancements—where researchers are currently engaged in two active clinical trials focused on emphysema treatment options while having conducted four prior studies that contributed valuable insights into tackling this condition; their work began with their initial recorded trial taking place just over a decade ago,in2010.

These institutions represent beacons of hope for those affected by emphysema—a progressive lung disease primarily caused by smoking or long-term exposure to air pollutants—and showcase how concerted efforts can lead us one step closer towards more effective management strategies and potentially even cures.It’s truly inspiring to witness the dedication and innovation taking place in hospitals across different locations, all working towards a common goal of improving the lives of emphysema patients worldwide.

Which are the best cities for emphysema clinical trials?

When it comes to emphysema clinical trials, several cities in the United States have emerged as prominent locations for research. Miami, Florida leads with 7 active trials focusing on treatments like Beclomethasone Dipropionate and INBRX-101 Q3W among others. Los Angeles, California follows closely behind with 6 ongoing studies that investigate various interventions including INBRX-101 Q3W and Doxycycline. New york, New York boasts 5 active trials exploring treatment options such as INBRX-101 Q3W and Doxycycline. Additionally, Philadelphia, Pennsylvania and Boston, Massachusetts each offer promising opportunities for individuals participating in emphysema clinical trials. These cities provide access to cutting-edge research aiming to improve outcomes and quality of life for those affected by emphysema.

Which are the top treatments for emphysema being explored in clinical trials?

Clinical trials are paving the way for new advancements in emphysema treatment. Among the top treatments being explored are:

  • Alpha-1 MP: Currently involved in two active trials and has a total of two emphysema trials since its first listing in 2013.
  • Doxycycline: Under investigation in one ongoing trial, with three all-time emphysema trials registered since 2009.
  • Alvelestat (MPH966): Being tested in one active trial and has a single recorded emphysema trial listed as of 2019.
  • Stereotactic Ablative Radiotherapy (SABR): Currently undergoing evaluation in one ongoing clinical trial, with one all-time registered emphysema trial dating back to 2013.

These treatments hold promise for improving outcomes and quality of life for individuals living with this chronic lung condition. As research progresses, we move closer to finding innovative solutions that can make a difference for those affected by emphysema.

What are the most recent clinical trials for emphysema?

Recent clinical trials offer hope for individuals with emphysema, a debilitating lung condition. INBRX-101 Q3W and Doxycycline have both shown promise in Phase 2 studies as potential treatments for emphysema. Additionally, Beclomethasone Dipropionate has entered Phase 3 trials to evaluate its effectiveness in managing this condition. These advancements highlight the ongoing efforts to find innovative therapies that can alleviate symptoms and improve the quality of life for those affected by emphysema.

What emphysema clinical trials were recently completed?

The University of Alabama at Birmingham recently concluded a clinical trial investigating the effectiveness of Belimumab in treating emphysema. This significant milestone, reached in August 2018, provides valuable insights into potential treatment options for individuals affected by this debilitating respiratory condition. The completion of this trial marks an important step forward in our collective efforts to improve outcomes and enhance quality of life for those living with emphysema.